KMT2A and acute myeloid leukemia: In the MLL-AF9 driven MOLM-13 cell line, mocetinostat reduced cell viability and induced apoptosis [83], while HDAC inhibitor I13 could be a potent and selective agent in AML patients with t(8;21) translocation or MLL-rearrangement to surmount differentiation block [84].